An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

Qin Huang(Broad Institute), Ken Y. Chan(Broad Institute), Jason Wu(Broad Institute), Nuria Roxana Botticello-Romero(Broad Institute), Zheng Qingxia(Broad Institute), Shan Lou(Broad Institute), Casey Keyes(Broad Institute), Alexander Svanbergsson(Broad Institute), Jencilin Johnston(Broad Institute), A. A. Mills(Broad Institute), C.-L. Lin(Broad Institute), Pamela P. Brauer(Broad Institute), Gabrielle Clouse(Broad Institute), Simon Pacouret(Broad Institute), John W. Harvey(Broad Institute), Thomas Beddow(Broad Institute), Jenna K. Hurley(Broad Institute), Isabelle G. Tobey(Broad Institute), Megan Powell(Broad Institute), Albert T. Chen(Broad Institute), Andrew J. Barry(Broad Institute), Fatma-Elzahraa Eid(Broad Institute), Yujia A. Chan(Broad Institute), Benjamin E. Deverman(Broad Institute)
Science
May 16, 2024
Cited by 160

Abstract

Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. The enhanced tropism was CNS-specific and absent in wild-type mice. When used to deliver GBA1 , mutations of which cause Gaucher disease and are linked to Parkinson’s disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared with AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.


Related Papers